Larimar Therapeutics (LRMR) Competitors $3.97 +0.26 (+7.01%) Closing price 04:00 PM EasternExtended Trading$4.06 +0.09 (+2.24%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LRMR vs. PRTA, CVAC, NUVB, AVXL, RLAY, CDMO, TYRA, QURE, ORIC, and CRMDShould you be buying Larimar Therapeutics stock or one of its competitors? The main competitors of Larimar Therapeutics include Prothena (PRTA), CureVac (CVAC), Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), Relay Therapeutics (RLAY), Avid Bioservices (CDMO), Tyra Biosciences (TYRA), uniQure (QURE), ORIC Pharmaceuticals (ORIC), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. Larimar Therapeutics vs. Prothena CureVac Nuvation Bio Anavex Life Sciences Relay Therapeutics Avid Bioservices Tyra Biosciences uniQure ORIC Pharmaceuticals CorMedix Prothena (NASDAQ:PRTA) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, community ranking, profitability, institutional ownership and media sentiment. Which has more risk and volatility, PRTA or LRMR? Prothena has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. Comparatively, Larimar Therapeutics has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Does the media favor PRTA or LRMR? In the previous week, Larimar Therapeutics had 10 more articles in the media than Prothena. MarketBeat recorded 18 mentions for Larimar Therapeutics and 8 mentions for Prothena. Prothena's average media sentiment score of 1.15 beat Larimar Therapeutics' score of 0.60 indicating that Prothena is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prothena 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Larimar Therapeutics 2 Very Positive mention(s) 7 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in PRTA or LRMR? Prothena received 565 more outperform votes than Larimar Therapeutics when rated by MarketBeat users. Likewise, 70.42% of users gave Prothena an outperform vote while only 70.00% of users gave Larimar Therapeutics an outperform vote. CompanyUnderperformOutperformProthenaOutperform Votes60770.42% Underperform Votes25529.58% Larimar TherapeuticsOutperform Votes4270.00% Underperform Votes1830.00% Do insiders and institutionals hold more shares of PRTA or LRMR? 97.1% of Prothena shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 28.2% of Prothena shares are held by insiders. Comparatively, 3.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is PRTA or LRMR more profitable? Larimar Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -98.86%. Prothena's return on equity of -24.19% beat Larimar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prothena-98.86% -24.19% -20.59% Larimar Therapeutics N/A -35.87%-32.37% Which has stronger valuation & earnings, PRTA or LRMR? Larimar Therapeutics has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProthena$91.37M8.66-$147.03M-$2.48-5.93Larimar TherapeuticsN/AN/A-$36.95M-$1.15-3.45 Do analysts prefer PRTA or LRMR? Prothena presently has a consensus price target of $46.50, suggesting a potential upside of 216.33%. Larimar Therapeutics has a consensus price target of $20.13, suggesting a potential upside of 406.93%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Prothena.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prothena 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Larimar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 SummaryLarimar Therapeutics beats Prothena on 10 of the 18 factors compared between the two stocks. Get Larimar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LRMR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LRMR vs. The Competition Export to ExcelMetricLarimar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$253.33M$6.90B$5.61B$9.12BDividend YieldN/A2.95%5.36%3.98%P/E Ratio-3.4510.0389.5417.51Price / SalesN/A348.831,227.0083.27Price / CashN/A65.0944.3037.67Price / Book2.135.295.124.72Net Income-$36.95M$154.95M$117.78M$224.62M7 Day Performance9.37%2.82%1.86%-0.42%1 Month Performance1.53%2.83%7.95%3.57%1 Year Performance-32.14%8.08%26.57%19.11% Larimar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LRMRLarimar Therapeutics1.724 of 5 stars$3.97+7.0%$20.13+406.9%-27.3%$253.33MN/A-3.4530Analyst ForecastNews CoveragePRTAProthena2.197 of 5 stars$16.09+3.0%$46.50+189.1%-53.2%$867.85M$91.37M-6.50130Analyst RevisionPositive NewsCVACCureVac4.2978 of 5 stars$3.77-2.0%$10.00+165.0%+4.6%$844.92M$58.18M6.861,172Positive NewsNUVBNuvation Bio2.3332 of 5 stars$2.48-1.8%$8.20+231.3%+38.8%$833.01MN/A-1.1460Short Interest ↑Analyst RevisionGap UpAVXLAnavex Life Sciences3.5086 of 5 stars$9.74-7.2%$44.00+351.8%+43.7%$826.06MN/A-18.7340Upcoming EarningsAnalyst ForecastRLAYRelay Therapeutics2.2413 of 5 stars$4.74-2.2%$20.50+332.1%-54.9%$799.24M$25.55M-1.83330Short Interest ↑CDMOAvid Bioservices2.3891 of 5 stars$12.45+0.2%$12.25-1.6%+69.5%$795.98M$139.91M-5.21320TYRATyra Biosciences2.8113 of 5 stars$15.50-2.4%$30.50+96.8%+5.8%$785.92MN/A-9.6520Gap UpQUREuniQure3.523 of 5 stars$15.76+0.5%$40.00+153.9%+154.4%$767.95M$15.84M-3.18500Analyst ForecastAnalyst RevisionNews CoverageORICORIC Pharmaceuticals4.3208 of 5 stars$10.74+3.9%$18.29+70.3%-4.8%$763.78MN/A-6.0180CRMDCorMedix2.5472 of 5 stars$12.40-0.1%$15.67+26.3%+237.0%$752.07M$60,000.00-15.3030Gap Down Related Companies and Tools Related Companies Prothena Alternatives CureVac Alternatives Nuvation Bio Alternatives Anavex Life Sciences Alternatives Relay Therapeutics Alternatives Avid Bioservices Alternatives Tyra Biosciences Alternatives uniQure Alternatives ORIC Pharmaceuticals Alternatives CorMedix Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LRMR) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrillion-Dollar Crypto PlayPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Larimar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
